Targeted Cancer Therapies & Biofluid Biopsies Agenda

Registration

Welcome Address

Speakers Introduction & Memento Presentation

Colvera™, A ctDNA Liquid Biopsy Assay for Colorectal Cancer. Our Journey from Discovery to the Clinic
Jason Ross, Sr Research Scientist And Team Leader, Commonwealth Scientific and Industrial Research Organisation, Australia

The speaker will discuss the journey that he and their collaborators undertook: from biomarker discovery and validation, to assay design and then to clinical trials and the launch of a commercial lab test.

nCounter Analysis System: Moving from Genomic Discovery to Translational Research
Jay Manikandan, Field Application Scientist, Nanostring Technologies

Q/A Discussion

Technology Spotlight:
Technological Advancements in Single Cell Analysis, helping in the Leukemia & Lymphoma Immunophenotyping and Circulating Tumor Cells Studies
Amitav Mohanty, Manager Market Development, Beckman Coulter

Coffee Break and Networking in Exhibition Area

OncoTrackTM - Validation of NGS based Liquid Biopsy Assay for Monitoring Cancer Treatment
Vidya H Veldore, Principal Scientist , MedGenome Labs Pvt Ltd

This presentation will focus on validation of plasma circulating tumor DNA as biomarker for genomic testing in NSCLC patients: MedGenome in collaboration with India's Premeir Cancer Hospital. Key aspects of validation of a clinical diagnostic assay that includes concordance assessment between tissue biopsy and plasma CtDNA for biomarker status, specificity, sensitivity and diagnostic accuracy of the testing will be discussed.

Q/A Discussion

Lunch Break and Networking in Exhibition Area

“Moonlighting Functions” of Glycolytic Enzymes as Emerging Targets for Preventing Cancer Cell Invasion and Metastasis
Hirak Basu, Associate Professor, University of Texas MD Anderson Cancer Center, United States of America

This talk will focus on novel therapeutic agents that target oxidative modifications in prostate cancer cells .It will also discuss how these agents are currently undergoing preclinical development for clinical trials.

Identifying Potential Therapeutic Targets in Gallbladder Cancer using Proteomic Strategies
Tejaswini Subbannayya, Research Scientist, Institute of Bioinformatics, India

This talk will highlight the potential therapeutic targets to improve Gallbladder cancer (GBC) treatment options and disease outcome. To this end, it will also discuss various proteomic strategies that were employed to study the pathobiology in GBC using GBC cell lines.

Q/A Discussion

Coffee Break and Networking in Exhibition Area

Integrating Peptide Drug Conjugates with Radiotherapy
Sunil J Advani, Associate Professor & Associate Division Director Clinical and Translational Research, University of California, San Diego, United States of America

Q/A Discussion

Open Discussion Session: Cancer Diagnosis and Treatment - The Oncologist’s Viewpoint
Experts: Vinayak V Maka, Associate Professor, Medical Oncology, Ramaiah Medical College and Hospitals, India Rohit; Raghunath Ranade, Consultant Gynecological Oncologist and Robotic Surgeon, Narayana Health Mazumdar Shaw Cancer Centre, India; Nanda Rajaneesh, Surgical Oncologist, Apollo Spectra Hospitals, India; K R Madhava, Medical Oncologist BGS Global Hospitals, India

Coffee & End of First Day of Conference

Draft Agenda- Subject to Change

Q/A Discussion

Coffee Break and Networking in Exhibition Area

NRF2-mediated changes in Glutathione Metabolism mediate the resistance of EGFR-T790M Mutant Lung Cancer Cells to Erlotinib
Olivier Pardo, Team Leader, Imperial College London, United Kingdom

The speaker will discuss about Metabonomics profiling of erlotinib-sensitive/resistant cells along with how, by using RNA interference and pharmacological inhibitors of GSH pathway enzymes, increasing GSH levels in ER cells sensitises these to erlotinib. Conversely, reducing GSH levels renders sensitive cells resistant to the drug. It will finally highlight how their data identifies a new resistance mechanism to EGFR TKIs and propose a novel therapeutic strategy to tackle this problem in the clinic.

Delineating Tobacco induced Cellular Transformations in Oral Cancer
Aditi Chatterjee, Faculty Scientist, Institute of Bioinformatics, India

This talk will discuss how both chewing and smoking tobacco causes oral cancer but the molecular alterations brought about by each insult is different. Amongst the proteins which was overexpressed in both smoked and smokeless form of tobacco was Stearoyl-CoA desaturase. The presenter will highlight that SCD can act as a potential therapeutic target in head and neck squamous cell carcinoma, especially in patients who are users of tobacco.

SBPL-0600: An Oncolytic Virotherapy with a Potential to Personalize Cancer Therapy
Vishwas Joshi, Director, Seagull BioSolutions Pvt Ltd, India

Signaling Mechanisms in Brain Tumor Initiating Cells
Neha Garg, Assistant Professor, IIT Mandi, India

Q/A Discussion

Lunch Break and Networking in Exhibition Area

Impact of Circulating Tumor Cells Heterogeneity for Monitoring Cancer Immunotherapy Effectiveness and Clinical Outcomes
Shibichakravarthy Kannan, Founder & CEO, Theranosis Life Sciences Pvt Ltd, India

Non Invasive Assessment of IL6 Levels in Patients with Oral Cancer
Susanna T, Assistant Professor, Sri Devaraj Urs Medical College, India

Q/A Discussion

Coffee Break and Networking in Exhibition Area

Case Study: Piramal Development Approach to an Early Phase ADC
Maria Kowal, Protein Scientist, Piramal Pharma Solutions, United Kingdom

Q/A Discussion

T11TS repress Glioma Mediated Apoptosis in Hematopoietic Stem Cells by Controlling both Extrinsic and Intrinsic Cascade of Cell Death and also rescue from Granzyme B Regulated Gliomagenic Killing
Somnath Mondal, PhD Fellow, Calcutta School of Tropical Medicine, Kolkata, India

Design of Novel Antagonists of Matrilysin through Advanced Pharmacophore based Virtual Screening and Molecular Dynamics Simulations
Sudheer Kumar Katari, Research Scholar, Sri Venkateswara Institute of Medical Sciences University, India

Complete Assignments of Extraction, Isolation and Characterization of Prostate Cancer Chemopreventive Compound Taraxerol from Bark Annona reticulata L. on Human Prostate Cancer Cell Line (LNCaP and PC-3 cell lines)
Saritha Surapaneni, Research Scholar, Acharya Bm Reddy College of Pharmacy, India

Signal Transduction Inhibitors from C. rotundus
Lydia Charles, Student, Bharathiar University, India

Q/A Discussion

Closing Remarks and Vote of Thanks

End of Conference